(Q43411812)

23 November 2017

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib (English)

1 reference

Markus Peck-Radosavljevic

23 November 2017

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author

16

1 reference

23 November 2017

M Pinter

1

1 reference

23 November 2017

W Sieghart

2

1 reference

23 November 2017

F Hucke

3

1 reference

23 November 2017

I Graziadei

4

1 reference

23 November 2017

W Vogel

5

1 reference

23 November 2017

A Maieron

6

1 reference

23 November 2017

R Königsberg

7

1 reference

23 November 2017

A Weissmann

8

1 reference

23 November 2017

G Kornek

9

1 reference

23 November 2017

J Matejka

10

1 reference

23 November 2017

R Stauber

11

1 reference

23 November 2017

R Buder

12

1 reference

23 November 2017

B Grünberger

13

1 reference

23 November 2017

M Schöniger-Hekele

14

1 reference

23 November 2017

C Müller

15

1 reference

23 November 2017

language of work or name

English

0 references

publication date

24 August 2011

1 reference

Alimentary Pharmacology & Therapeutics

23 November 2017

1 reference

23 November 2017

34

1 reference

23 November 2017

8

1 reference

23 November 2017

949-959

1 reference

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

23 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Updated treatment approach to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Hepatocellular carcinoma in Central Europe: prognostic features and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Review article: the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Evolution of prognostic factors in hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04823.X

10.1111/J.1365-2036.2011.04823.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference